β-caryophyllene Enhances Cancer Treatment in Liver Cancer Cells
Author Information
Author(s): Basheer Irum, Wang Hai, Li Guangyue, Jehan Shah, Raza Ali, Du Chentao, Ullah Najeeb, Li Dangdang, Sui Guangchao
Primary Institution: Key Laboratory of Saline-Alkali Vegetation Ecology Restoration, Ministry of Education, College of Life Science, Northeast Forestry University, Harbin, China
Hypothesis
Does β-caryophyllene (BCP) enhance the effectiveness of chemotherapeutics in hepatocellular carcinoma (HCC) cells?
Conclusion
BCP sensitizes HCC cells to chemotherapeutics while reducing toxicity to normal liver cells.
Supporting Evidence
- BCP reduced HCC cell proliferation with IC50 values of 193.60 μM for HepG2 cells.
- BCP enhanced the cytotoxicity of doxorubicin and cisplatin in HCC cells.
- RNA-seq analysis identified 433 differentially expressed genes in BCP-treated HepG2 cells.
- BCP treatment reduced migration and invasion of HCC cells.
Takeaway
BCP is a natural compound that helps cancer medicines work better against liver cancer without hurting normal liver cells too much.
Methodology
HCC cells were treated with BCP, doxorubicin, and cisplatin, followed by assays to evaluate cell proliferation, migration, and gene expression.
Limitations
The study used only two HCC cell lines, which may not represent all cancer types.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website